Literature DB >> 26504448

Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder.

Yi-Sik Kim, Sang-Rok Lee.   

Abstract

Stent thrombosis is a life-threatening sequela of drug-eluting stent implantation. Dual antiplatelet therapy with aspirin and thienopyridine is typically used to prevent this catastrophic event. In terms of stent thrombosis, the major concern is the variable response of patients to clopidogrel, and this has raised interest in new antiplatelet agents. We present the case of a 64-year-old woman whom we successfully treated with prasugrel after she had repeated episodes of stent thrombosis caused by a poor response to clopidogrel. This case highlights the potential role of new antiplatelet agents for patients who are undergoing drug-eluting stent implantation.

Entities:  

Keywords:  Clopidogrel; coronary disease/therapy; coronary restenosis/etiology/physiopathology/prevention & control; drug resistance; drug therapy/combination; drug-eluting stents/adverse effects; platelet aggregation inhibitors/therapeutic use; prasugrel; thrombosis/etiology/prevention & control; treatment outcome

Mesh:

Substances:

Year:  2015        PMID: 26504448      PMCID: PMC4591894          DOI: 10.14503/THIJ-14-4491

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  15 in total

1.  Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization.

Authors:  Joseph E Mobley; Stuart J Bresee; Dale C Wortham; Robert M Craft; Carolyn C Snider; Roger C Carroll
Journal:  Am J Cardiol       Date:  2004-02-15       Impact factor: 2.778

2.  Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation.

Authors:  Tobias Geisler; Harald Langer; Magdalena Wydymus; Katrin Göhring; Christine Zürn; Boris Bigalke; Konstantinos Stellos; Andreas E May; Meinrad Gawaz
Journal:  Eur Heart J       Date:  2006-09-27       Impact factor: 29.983

Review 3.  Late coronary stent thrombosis.

Authors:  Stephan Windecker; Bernhard Meier
Journal:  Circulation       Date:  2007-10-23       Impact factor: 29.690

4.  Clinical end points in coronary stent trials: a case for standardized definitions.

Authors:  Donald E Cutlip; Stephan Windecker; Roxana Mehran; Ashley Boam; David J Cohen; Gerrit-Anne van Es; P Gabriel Steg; Marie-angèle Morel; Laura Mauri; Pascal Vranckx; Eugene McFadden; Alexandra Lansky; Martial Hamon; Mitchell W Krucoff; Patrick W Serruys
Journal:  Circulation       Date:  2007-05-01       Impact factor: 29.690

Review 5.  Drug insight: Clopidogrel nonresponsiveness.

Authors:  Paul A Gurbel; Udaya S Tantry
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2006-07

6.  Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis.

Authors:  Seung-Whan Lee; Seong-Wook Park; Myeong-Ki Hong; Young-Hak Kim; Bong-Ki Lee; Jong-Min Song; Ki Hoon Han; Cheol Whan Lee; Duk-Hyun Kang; Jae-Kwan Song; Jae-Joong Kim; Seung-Jung Park
Journal:  J Am Coll Cardiol       Date:  2005-10-19       Impact factor: 24.094

7.  Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.

Authors:  Piergiovanni Buonamici; Rossella Marcucci; Angela Migliorini; Gian Franco Gensini; Alberto Santini; Rita Paniccia; Guia Moschi; Anna Maria Gori; Rosanna Abbate; David Antoniucci
Journal:  J Am Coll Cardiol       Date:  2007-06-04       Impact factor: 24.094

8.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

9.  Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study.

Authors:  Young-Hoon Jeong; Seung-Whan Lee; Bong-Ryong Choi; In-Suk Kim; Myung-Ki Seo; Choong Hwan Kwak; Jin-Yong Hwang; Seong-Wook Park
Journal:  J Am Coll Cardiol       Date:  2009-03-31       Impact factor: 24.094

10.  Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.

Authors:  Gilles Montalescot; Stephen D Wiviott; Eugene Braunwald; Sabina A Murphy; C Michael Gibson; Carolyn H McCabe; Elliott M Antman
Journal:  Lancet       Date:  2009-02-28       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.